SPPI, DNDN , JAZZ this goes from 0.8 to double figure..
ADAM'S Bashing was PROVED WRONG on all these companies when these companies were traded as Penny Stocks.
- BIO-T-GEL would enter $1.6Billion according to IMS Health, Mkt Segment as........ GEL formulation and NOT PATCH like ABBOTT LABS.
Current methods of administration include testosterone injections, patches and gels. Testosterone injections require large needles, are often painful and not effective for maintaining adequate testosterone blood levels throughout the day. Delivery of testosterone through transdermal patches was developed primarily to promote the therapeutic effects of testosterone therapy without the often painful side effects associated with testosterone injections. Transdermal patches, however, similar to estrogen patches, have a physical presence, can fall off, and can result in skin irritation.
Bio-T- Gel - Testosterone formulated gel products for men are designed to deliver testosterone without the pain of injections and the physical presence, skin irritation and discomfort associated with transdermal patches.
LibiGel — once daily transdermal testosterone gel completed Phase III clinical trials and Special Protocol Assessment (SPA) for the treatment of female sexual dysfunction (FSD).NDA would be by end of 1st Quarter 2012.
Elestrin — once daily transdermal estradiol (estrogen) gel approved by the U.S. Food and Drug Administration (FDA) indicated for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause and marketed in the U.S.
AI
